Relationship between Patients’ Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Table 2

Differences in overall survival associated with immunotherapy in sex by subgroups.

		Participants, no.		Pooled HR (95% CI) for ICI vs. controlled therapies		Test for difference
Variable	Studies, no.	Male	Female	Male	Female	value
Overall	18	8881	4430	0.77 (0.72, 0.82)	0.77 (0.67, 0.87)	0.955
Line of therapy
First	11	5460	2748	0.78 (0.72, 0.86)	0.74 (0.61, 0.89)	0.596
Subsequent	7	3421	1682	0.75 (0.69, 0.82)	0.80 (0.67, 0.96)	0.571
Intervention therapy
ICI alone	11	5128	2717	0.74 (0.68, 0.80)	0.82 (0.73, 0.92)	0.13
ICI combined with non-ICI	7	3753	1713	0.83 (0.76, 0.90)	0.68 (0.51, 0.91)	0.201
Pathologic types
Squamous	4	1855	408	0.76 (0.63, 0.93)	0.73 (0.46, 1.17)	0.886
Nonsquamous	5	2425	1605	0.80 (0.72, 0.89)	0.67 (0.51, 0.89)	0.252

Abbreviations: HR = hazard ratio; ICI = immune checkpoint inhibitor.